Questions? +1 (202) 335-3939 Login
Trusted News Since 1995
A service for global professionals · Sunday, November 18, 2018 · 468,673,899 Articles · 3+ Million Readers

Integral BioSystems Enhances IP Asset Valuation with Broad Patent Allowance of its NanoM™ Sustained Release Platform

The USPTO has issued a broad allowance on a patent application for Integral BioSystems’ NanoM, the firm’s sustained release platform formulation technology.

More effective treatment with fewer applications of drug. It's a genuine win-win proposition.”
— Dr. Shikha Barman
BEDFORD, MA, US, December 5, 2017 / -- Boston-area drug development firm Integral BioSystems has received patent allowance from the USPTO on another of its flagship inventions, NanoM™, hot on the heels of allowance by the USPTO of Integral’s OcuSurf™, another of Integral’s platform technologies to enhance bioavailability.

Envisioned as a platform for the formulation of new chemical entities as well as already-approved drugs in a 505b2 environment, NanoM technology is a novel, patented, differentiated and improved delivery approach for administering sustained-release medications, both small molecules and biologics to ocular and other tissue types, both as therapies adjunct to surgical interventions as well as stand-alone sustained release drug therapies in ophthalmology, urology and other accessible tissue spaces. The NanoM technology is applied as a biodegradable, nanostructured wafer that has key characteristics unique to its drug release and tissue biocompatibility. This is particularly useful for the development of improved, next-generation therapies in ophthalmic indications in glaucoma, cataract surgery, etc. as well as the development of regimens to treat cancer and infections for other tissues and organs. This innovation can be considered transformational and can be the platform engine for many future sustained release products.

Integral BioSystems is developing an ophthalmic pipeline utilizing NanoM technology. As a business strategy, Integral is considering licensing-based R&D feasibility collaborations from companies seeking innovative technologies in ophthalmic, urology, otic, intranasal, intra-uterine and rectal routes using new drug substances, as well as using approved drugs to pursue an aggressive 505b2 development strategy.

About Integral BioSystems
Since its formation in 2011, Integral BioSystems has established credibility in drug formulation, CMC consulting, analytical method development and methods qualification, as well as scale-up process engineering. Along with its strong presence as an ophthalmic product development CRO, the company also has expertise in other routes, including injectables, infusions, topical dermal gels/creams, and nanocrystals. Integral BioSystems provides expertise and know-how in developing both front-of-the-eye and back-of-the-eye products, offering complete development services in pre-formulation, including bioanalytical.

For companies seeking to develop a new product that is using a re-purposed drug, Integral offers its innovative delivery systems as licensable technologies to build value into prospective clients’ drug products through a 505b2 regulatory strategy. For companies seeking product life cycle management, Integral can help them quickly ascertain if Integral’s innovations can provide the desired improvements. With multiple billion dollar drug products going off-patent, this presents a cost effective way to develop an extended product life cycle with novel IP. In this manner, Integral will offer its insight and technological innovations in drug delivery to strategize and improve the customer’s product portfolio. To this effect, Integral BioSystems has been a development partner for both innovative and generic companies.

Dave Karasic
Integral BioSystems, LLC
email us here

Powered by EIN Presswire